# Tinlarebant PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tinlarebant

> The PDUFA target action date for tinlarebant, sponsored by BELITE BIO, INC (BLTE), is February 12, 2027. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the tinlarebant PDUFA date?

The PDUFA target action date for tinlarebant, sponsored by BELITE BIO, INC (BLTE), is February 12, 2027. Status: scheduled. Press release filed with the SEC (EX-99): "Fee Act (PDUFA) target action date of February 12, 2027" Last confirmed November 12, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/tinlarebant)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-125573, https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/tinlarebant#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | tinlarebant |
| Codes | LBS-008 |
| Sponsor | BELITE BIO, INC (BLTE) https://sec-api.dev/companies/blte/catalysts |
| Indications | ga associated with dry amd, Stargardt Disease 1, STGD1, [Geographic Atrophy](https://sec-api.dev/indications/geographic-atrophy) |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### Jul 2023: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: GA associated with dry AMD.
- First seen 2026-03-31, last confirmed 2026-03-31.
- SEC Form 10-K (accession 0001104659-26-037374): "In addition, we have initiated our Phase 3 trial named "PHOENIX" to evaluate the safety and efficacy of tinlarebant in patients with GA associated with dry AMD, and have randomized the first subject in July 2023." https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm

### late 2024: interim data readout

- Status: scheduled. Date confidence: half.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-24-116159): "Company expects to report interim analysis by end of 2024 or early 2025" https://www.sec.gov/Archives/edgar/data/1889109/000110465924116159/tm2427528d1_ex99-1.htm

### August 4, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Stargardt Disease 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05244304 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-04 (ACTUAL); Lead Sponsor Belite Bio, Inc." https://clinicaltrials.gov/study/NCT05244304

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-02-27, last confirmed 2025-03-17.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-024128): "Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)" https://www.sec.gov/Archives/edgar/data/1889109/000110465925024128/tm258947d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-017817): "An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned interim efficacy analysis; trial completion expected by Q4 2025 (including a three-month follow-up period)" https://www.sec.gov/Archives/edgar/data/1889109/000110465925017817/tm257795d1_ex99-1.htm

### Q2 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-03-31, last confirmed 2026-03-31.
- SEC Form 10-K (accession 0001104659-26-037374): "Although we announced the top-line results of the Phase 3 DRAGON in December 2025 and we expect to submit an NDA to the FDA in the second quarter of 2026, the foregoing risks regarding marketing approvals remain applicable to tinlarebant." https://www.sec.gov/Archives/edgar/data/1889109/000110465926037374/blte-20251231x20f.htm

### Aug 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125573): "In August 2026, the FDA accepted the NDA for tinlarebant in STGD1 and granted" https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm

### Sep 2026: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125573): "The Company submitted a J-NDA to the Ministry of Health, Labour and Welfare (MHLW) in Japan for tinlarebant in STGD1 in September 2026." https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm

### February 12, 2027: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-08-11, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125573): "Fee Act (PDUFA) target action date of February 12, 2027" https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125573): "Priority Review, with an assigned PDUFA target action date of February 12, 2027." https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-125573): ""As we advance toward our PDUFA target action date of February 12, 2027, we remain focused on commercial readiness and are energized by the potential to bring a first-ever treatment to people living with STGD1," said Dr. Tom Lin, Chairman and Chief Executive Officer of Belite Bio." https://www.sec.gov/Archives/edgar/data/1889109/000110465926125573/tm2629321d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095218): "User Fee Act (PDUFA) target action date of February 12, 2027" https://www.sec.gov/Archives/edgar/data/1889109/000110465926095218/tm2623018d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095218): "FDA had accepted the NDA submission and granted Priority Review, with an assigned PDUFA target action date of February 12, 2027." https://www.sec.gov/Archives/edgar/data/1889109/000110465926095218/tm2623018d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-094040): "The FDA has set a Prescription Drug User Fee Act (PDUFA) date of February 12, 2027." https://www.sec.gov/Archives/edgar/data/1889109/000110465926094040/tm2622827d1_ex99-1.htm

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Geographic Atrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05949593 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Belite Bio, Inc." https://clinicaltrials.gov/study/NCT05949593

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Geographic Atrophy.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05949593 (Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Belite Bio, Inc." https://clinicaltrials.gov/study/NCT05949593

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: STGD1; Stargardt Disease 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06388083 (A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Belite Bio, Inc." https://clinicaltrials.gov/study/NCT06388083

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: STGD1; Stargardt Disease 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06388083 (A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-02 (ESTIMATED); Lead Sponsor Belite Bio, Inc." https://clinicaltrials.gov/study/NCT06388083

## Same indication

- [JNJ-81201887](https://sec-api.dev/pdufa/jnj-81201887) (JNJ)
- [Vonaprument](https://sec-api.dev/pdufa/vonaprument) (ANNX)

Calendar months: [February 2027](https://sec-api.dev/fda-calendar/2027-02), [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tinlarebant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tinlarebant PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tinlarebant

```bibtex
@misc{secapidev_pdufa_tinlarebant_20261116,
  title        = {Tinlarebant PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tinlarebant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tinlarebant_20261116","title":"Tinlarebant PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tinlarebant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
